2012最新国际宫颈癌筛查指南课件.ppt

我们可以看一下这张图：HPV感染后以整合和非整合两种状态存在于宿主细胞，目前常用的细胞学检查的HPV感染后导致的细胞形态学改变，而HPV-DNA的检测有助于HPV感染者的临床诊治管理 * * 国外因为专利问题因此取得FDA注册产品的原理都不相同 * 国产的就更多了，但检测方法基本分为几类：1. PCR－反向点杂交（PCR－膜杂交）；2. PCR-荧光探针法；3. 流式荧光杂交法 * 国外因为专利问题因此取得FDA注册产品的原理都不相同 * * * *  * The ACS/ASCCP/ASCP Guidelines provide two approaches for screening women ages 30-65. They can be screened by co-testing with HPV and cytology every 5 years (preferred) or screened every 3 years with cytology alone (acceptable) The schematic depicted on this slide shows the preferred recommendation for women ages 30-35. -Women with ASC-US who are also high-risk HPV+ AND women with LSIL regardless of HPV status go to colposcopy. -Women who are HPV negative and either normal or ASC-US cytology are considered safe to return to routine screening in 5 years. -Women who have normal cytology and are HPV+ have two options for management. They can either return for a co-test in 1 year The can be managed depending upon their high-risk HPV genotype. -Women with HPV16 or HPV18 go to colposcopy -Women who are not positive for HPV16 or HPV18 return for a co-test in 1 year. For those who require repeat co-testing: -Those who have are persistently HPV+ AND those with LSIL regardless of HPV status go to colposcopy. -Those who are HPV negative and do not have LSIL regardless are considered safe to return to routine screening in 5 years. * * Guidelines released by the American Society for Colposcopy and Cervical Pathology recommend a new strategy for screening Co-testing is becoming the new gold standard of screening and is designed to provide a safety net that helps detect cases of cervical cancer that may have otherwise been missed using Pap alone * * page * ? 2010 Roche page * ? 2010 Roche STRICTLY CONFIDENTIAL – FOR INTERNAL USE ONLY. NOT FOR DISTRIBUTION ? 2010 Roche STRICTLY CONFIDENTIAL – FOR INTERNAL USE ONLY. NOT FOR DISTRIBUTION page * ? 2010 Roche page * ? 2010 Roche HPV -DNA检测现状及2012最新国际宫颈癌筛查指南